Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: faricimab, pegaptanib octasodium, vanucizumab +10 | 0.90 |
| trials ClinicalTrials.gov | 8 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 35 Parkinson's papers of 15,183 | 0.53 |
| pathways Reactome | 10 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 2558
Sealed predictions
- VEGFA in dopamine neurons, braak-0.25 (p 0.508) → +0.11 (p 0.787)receipt 2566
Swarm cases
receipt 2566: VEGFA in dopamine neurons, braak
- power
- full sample -0.05 (p 0.834, n 18), 95% CI -0.51 to +0.42. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.01 (p 0.956, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.06 (p 0.820, n 18). could be the mix.
- skeptic
- leave-one-out range -0.22 to +0.05, sign flips 4; without severely affected donors -0.05 (p 0.834, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for VEGFA in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts